These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 31263528

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Real pandemic world results of pharmacokinetic-tailored personalized prophylaxis of bleeds in Polish children and adolescents with severe hemophilia A.
    Urasiński T, Paczóska K, Badowska W, Bobrowska H, Dakowicz Ł, Dobaczewski G, Latos-Grażyńska E, Karolczyk G, Klukowska A, Kołtan A, Wojdalska M, Łaguna P, Niedźwiedzki M, Pietrys D, Radoń-Proskura J, Radwańska M, Rurańska I, Szczepański T, Wasiński D, Woźnica-Karczmarz I, Zielezińska K, Królak A, Ociepa T.
    Front Pediatr; 2023; 11():1084539. PubMed ID: 36911027
    [Abstract] [Full Text] [Related]

  • 23. Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A.
    Astermark J, Olsson A, Chelle P, Täckström K, Walger M, Magnusson M, Iorio A.
    Haemophilia; 2021 Jul; 27(4):626-633. PubMed ID: 33966319
    [Abstract] [Full Text] [Related]

  • 24. Development, upscaling and validation of the purification process for human-cl rhFVIII (Nuwiq®), a new generation recombinant factor VIII produced in a human cell-line.
    Winge S, Yderland L, Kannicht C, Hermans P, Adema S, Schmidt T, Gilljam G, Linhult M, Tiemeyer M, Belyanskaya L, Walter O.
    Protein Expr Purif; 2015 Nov; 115():165-75. PubMed ID: 26318235
    [Abstract] [Full Text] [Related]

  • 25. Personalised Prophylaxis in a Child with Haemophilia A and Type 1 Diabetes.
    Cruz MS, Santillan J, Lesser J, Ortiz JP, Forzani L.
    Clin Pract; 2021 May 08; 11(2):287-292. PubMed ID: 34066835
    [Abstract] [Full Text] [Related]

  • 26. A new paradigm for personalized prophylaxis for patients with severe haemophilia A.
    Delavenne X, Ollier E, Lienhart A, Dargaud Y.
    Haemophilia; 2020 Mar 08; 26(2):228-235. PubMed ID: 32100950
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Continuous infusion of simoctocog alfa in haemophilia A patients undergoing surgeries.
    Holme PA, Tjønnfjord GE.
    Haemophilia; 2019 Jan 08; 25(1):54-59. PubMed ID: 30394617
    [Abstract] [Full Text] [Related]

  • 29. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
    Lentz SR, Janic D, Kavakli K, Miljic P, Oldenburg J, C Ozelo M, Santagostino E, Suzuki T, Zupancic Šalek S, Korsholm L, Matytsina I, Tiede A.
    Haemophilia; 2018 Nov 08; 24(6):e391-e394. PubMed ID: 30402994
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A.
    Takedani H, Hirose J.
    Drug Des Devel Ther; 2015 Nov 08; 9():1767-72. PubMed ID: 25848213
    [Abstract] [Full Text] [Related]

  • 33. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.
    Mullins ES, Stasyshyn O, Alvarez-Román MT, Osman D, Liesner R, Engl W, Sharkhawy M, Abbuehl BE.
    Haemophilia; 2017 Mar 08; 23(2):238-246. PubMed ID: 27891721
    [Abstract] [Full Text] [Related]

  • 34. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
    Lusher JM.
    Haematologica; 2000 Oct 08; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.
    Korth-Bradley JM, Rendo P, Smith L, Altisent C.
    Clin Ther; 2016 Apr 08; 38(4):936-44. PubMed ID: 26969334
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII.
    Gringeri A, Tagliaferri A, Tagariello G, Morfini M, Santagostino E, Mannucci P, ReFacto-AICE Study Group.
    Br J Haematol; 2004 Aug 08; 126(3):398-404. PubMed ID: 15257713
    [Abstract] [Full Text] [Related]

  • 38. Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: descriptive meta-analysis of post-marketing study data.
    Yoshioka A, Fukutake K, Takamatsu J, Shirahata A, Kogenate Post-Marketing Surveillance Study Group.
    Int J Hematol; 2006 Aug 08; 84(2):158-65. PubMed ID: 16926139
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
    Kulkarni R, Karim FA, Glamocanin S, Janic D, Vdovin V, Ozelo M, Rageliene L, Carboni E, Laguna P, Dobaczewski G, Seremetis S, Lindblom A, Santagostino E.
    Haemophilia; 2013 Sep 08; 19(5):698-705. PubMed ID: 23651313
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.